Quick answer
What is LL-37?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk How this site works
LL-37 is a peptide, grouped on this site under Tissue repair peptides, and the 12 research records kept here are 6 from studies in rats or mice and 6 that do not state what kind of study it is.
The literature search returned 2,666 records. This site keeps 12 of them, which is 0.45 per cent of what came back.
What it is
This site puts it in the Tissue repair peptides group.
A human cathelicidin antimicrobial peptide; the retrieved records report direct antimicrobial activity and signalling through formyl peptide receptor-like 1.[1, 2]
Stated in the titles of the cited 1998 Antimicrobial Agents and Chemotherapy and 2000 Journal of Experimental Medicine papers.
What kind of records
The records kept here are animal and laboratory studies only.
That sentence is produced by counting, not by reading. What was counted: no interventional human trial record; 6 rodent and 0 in vitro records among 12.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 2,654 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrobial agents and chemotherapy (1998). pmid:9736536
- LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. The Journal of experimental medicine (2000). pmid:11015447